tiprankstipranks
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
US Market
Holding EPIX?
Track your performance easily

ESSA Pharma (EPIX) Income Statement

274 Followers

ESSA Pharma Income Statement

Last quarter (Q4 2024), ESSA Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, ESSA Pharma's net income was $-6.36M. See ESSA Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 24Sep 23Sep 22Sep 21Sep 20
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 34.42M$ 34.42M$ 32.14M$ 36.96M$ 37.17M$ 24.14M
Operating Income
$ -34.42M$ -34.42M$ -32.13M$ -36.95M$ -37.12M$ -22.90M
Net Non Operating Interest Income Expense
$ 5.87M$ 5.87M$ 5.55M$ -1.72M$ 235.00K-
Other Income Expense
$ 1.63M-$ 6.53K$ 22.04K$ -107.02K$ 110.86K
Pretax Income
$ -28.54M$ -28.54M$ -26.58M$ -35.22M$ -36.84M$ -23.73M
Tax Provision
$ -10.00K$ -10.00K$ 1.60K$ -111.82K$ -34.35K$ -288.65K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -28.54M$ -28.54M$ -26.58M$ -35.10M$ -36.81M$ -23.45M
Basic EPS
$ -0.64$ -0.64$ -0.60$ -0.80$ -0.96$ -1.04
Diluted EPS
$ -0.64$ -0.64$ -0.60$ -0.80$ -0.96$ -1.04
Basic Average Shares
$ 177.11M$ 44.28M$ 44.09M$ 44.04M$ 38.48M$ 22.44M
Diluted Average Shares
$ 177.11M$ 44.28M$ 44.09M$ 44.04M$ 38.48M$ 22.44M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 34.42M$ 34.42M$ 32.14M$ 36.96M$ 37.17M$ 24.14M
Net Income From Continuing And Discontinued Operation
$ -28.54M$ -28.54M$ -26.58M$ -35.10M$ -36.81M$ -23.45M
Normalized Income
$ -19.43M$ -28.55M--$ -36.87M-
Interest Expense
------
EBIT
$ -28.55M$ -28.55M$ -26.58M$ -35.20M$ -36.82M$ -23.12M
EBITDA
$ -28.04M$ -28.46M$ -26.46M$ -34.94M$ -36.71M$ -23.01M
Currency in USD

ESSA Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis